

Akebia Therapeutics, Inc.  
 Form 3  
 March 18, 2016

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â Dahan Michel  
 (Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS,  
 INC.,Â 245 FIRST STREET,  
 SUITE 1100

(Street)

CAMBRIDGE,Â MAÂ 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)  
 03/10/2016

3. Issuer Name and Ticker or Trading Symbol  
 Akebia Therapeutics, Inc. [AKBA]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 SVP, Chief Business Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	27,261	D	Â
Common Stock	20,500 <sup>(1)</sup>	D	Â
Common Stock	28,596 <sup>(2)</sup>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

## Edgar Filing: Akebia Therapeutics, Inc. - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date <small>(Month/Day/Year)</small>		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	Â (3)	02/22/2026	Common Stock	30,950	\$ 7.7	D	Â
Stock Option (Right to Buy)	Â (4)	09/30/2025	Common Stock	15,000	\$ 9.66	D	Â
Stock Option (Right to Buy)	Â (5)	03/06/2025	Common Stock	30,000	\$ 11.15	D	Â
Stock Option (Right to Buy)	Â (6)	05/14/2024	Common Stock	6,667	\$ 22.8	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Dahan Michel C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET, SUITE 1100 CAMBRIDGE, MA 02142	Â	Â	Â SVP, Chief Business Officer	Â

## Signatures

/s/ Nicole R. Hadas, attorney-in-fact for Michel Dahan 03/18/2016

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock units were granted by the Issuer on February 22, 2016 pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the Grant Date.  
These shares are restricted stock issued pursuant to the December 23, 2013 restricted stock agreement. The shares will vest as follows:
  - (2) 25% vested on December 2, 2014, and the remaining shares will vest in equal quarterly installments over the following three years through December 2, 2017.
  - (3) This option was granted February 22, 2016. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
  - (4) This option was granted September 30, 2015. 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
  - (5) This option was granted March 6, 2015. 25% of this option vested on the first anniversary of the grant date and the remaining 75% will vest in equal quarterly installments thereafter.
  - (6) This option was granted May 14, 2014. 25% of this option vested on the first anniversary of the grant date and the remaining 75% will vest in equal quarterly installments thereafter.

^

**Remarks:**

Exhibit^ List

Exhibit^ 24^ -^ Limited^ Power^ of^ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.